Trial
NCT00302952
Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
Autoimmunity Centers of Excellence
Condition
Rheumatoid Arthritis
Intervention
Lovastatin
Why stopped
Slow enrollment \&Study Drug Expiration (Target: 40 randomized participants /arm)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-09-07